RT Journal Article
T1 Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study.
A1 Ríos, A
A1 Rodríguez, M A
A1 Puñal, J A
A1 Moreno, P
A1 Mercader, E
A1 Ferrero, E
A1 Ruiz-Pardo, J
A1 Morlán, M A
A1 Martín, J
A1 Durán-Poveda, M
A1 Bravo, J M
A1 Casanova, D
A1 Egea, M P Salvador
A1 Torregrosa, N M
A1 Exposito-Rodríguez, A
A1 Martínez-Fernández, G
A1 Carrión, A M
A1 Vidal, O
A1 Herrera, F
A1 Ruiz-Merino, G
A1 Rodríguez, J M
K1 Familial papillary microcarcinoma
K1 Familial papillary thyroid carcinoma
K1 Papillary thyroid carcinoma
K1 Papillary thyroid microcarcinoma
K1 Recurrence
AB Familial papillary thyroid microcarcinoma (FPTMC) can present a more aggressive behavior than the sporadic microcarcinoma. However, few studies have analyzed this situation. The objective is to analyze the recurrence rate of FPTMC and the prognostic factors which determine that recurrence in Spain. Spanish multicenter longitudinal analytical observational study was conducted. Patients with FPTMC received treatment with curative intent and presented cure criteria 6 months after treatment. Recurrence rate and disease-free survival (DFS) were analyzed. Two groups were analyzed: group A (no tumor recurrence) vs. group B (tumor recurrence). Ninety-four patients were analyzed. During a mean follow-up of 73.3 ± 59.3 months, 13 recurrences of FPTMC (13.83%) were detected and mean DFS was 207.9 ± 11.5 months. There were multifocality in 56%, bilateral thyroid involvement in 30%, and vascular invasion in 7.5%; that is to say, they are tumors with histological factors of poor prognosis in a high percentage of cases. The main risk factors for recurrence obtained in the multivariate analysis were the tumor size (OR: 2.574, 95% CI 1.210-5.473; p = 0.014) and the assessment of the risk of recurrence of the American Thyroid Association (ATA), both intermediate risk versus low risk (OR: 125, 95% CI 10.638-1000; p  FPTMC has a recurrence rate higher than sporadic cases. Poor prognosis is mainly associated with the tumor size and the risk of recurrence of the ATA.
YR 2022
FD 2022-10-17
LK http://hdl.handle.net/10668/20064
UL http://hdl.handle.net/10668/20064
LA en
DS RISalud
RD Apr 11, 2025